Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

Gecse, K; D. Lovász, Barbara; Farkas, Klaudia; Banai, János; Bene, László; Gasztonyi, Beáta; A. Golovics, Petra; Kristóf, Tünde; Lakatos, László; Csontos, Á; Juhász, Márk; Nagy, Ferenc; Palatka, Károly; Papp, Mária; V. Patai, Árpád; Lakner, Lilla; Salamon, Á; Szamosi, Tamás; Szepes, Zoltán; Tamás Tóth, Gábor; Vincze, Áron; Szalay, Balázs; Molnár, Tamás; L. Lakatos, Péter

doi:10.1093/ecco-jcc/jjv220

Public

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

Published in Journal of Crohn s and Colitis • Dec 10, 2015

Authors:

K Gecse

Barbara D. Lovász

Klaudia Farkas

Abstract

BACKGROUND AND AIMS: Biosimilar infliximab CT-P13 is approved for all indications of the originator product in Europe. Prospective data on its efficacy, safety, and immunogenicity in inflammatory bowel diseases are lacking. METHODS: A prospective, nationwide, multicentre, observational cohort was de...

Subject

Biosimilar

Medicine

Infliximab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!